Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 213-218

  Kaplan, Henry G ^a   Malmgren, Judith A ^b,c   Atwood, Mary ^a   Goldstein, Lynn C ^d  

^a SWEDISH MEDICAL CENTER   (United States)

^b HealthStat Consulting Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d PHENOPATH LABORATORIES   (United States)

Author keywords

Anthracycline therapy; Neoadjuvant chemotherapy; Response rates

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SATELLITE DNA;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ARTIFACT; ASSAY; AUTOFLUORESCENCE; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; CELL COUNT; CENTROMERE; CHROMOSOME 17P; CHROMOSOME 17Q; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; MORPHOMETRICS; MULTIPLE CYCLE TREATMENT; NUMERICAL CHROMOSOME ABERRATION; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; POLYSOMY 17; TISSUE SECTION;

EID: 77957156876     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: None     Document Type: Article

References (21)

1. Konecny GE, Pauletti G, Untch M, et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat. 2010; doi: 10.1007/s10549-010-0744-z.
2. Bartlett JMS, Munro A, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008;26:5027-5035.
3. Kawachi K, Sasaki T, Murakami A, et al. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy. Pathol Res Practice. 2010; doi: 10.1016/j.prp.2009.10.009.
4. Rody A, Karn T, Gatje R, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007;16:86-93.
5. Orlando L, Del Curto B, Gandini S, et al. Topoisomerase IIα gene status and prediction of pathological complete remission after anthracyclinebased neoadjuvant chemotherapy in endocrine nonresponsive Her2/ neu-positive breast cancer. Breast. 2008;17:506-511.
6. Arpino G, Ciocca DR, Weiss H, et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat. 2005;92:69-75.
7. Gennari A, Sormani M, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100(1):14-20.
8. Bartlett JMS, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet. 2010; doi: 10.1016/s1470-2045(10)70006-1.
9. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long- survival in patients with triple-negative breast cancer. J Clin Onc. 2008;25(8):1275-1281.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
11. SPSS Version 17.0. Chicago: SPSS, Inc. 2009.
12. Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. San Antonio Breast Cancer Symposium. 2008;705 [abstract].
13. Hanneman J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy. British J Cancer. 2006;95: 1334-1341.
14. Rody A, Karn T, Ruckhaberle E, et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat. 2009;113:457-466.
15. Oakman C, Moretti E, Galardi F, et al. The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev. 2009;35:662-667.
16. Pritchard KL, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008;26:736-744.
17. Devita VT, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment for cancer. Cancer. 1975;35:98-110.
18. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007;13:2329-2334.
19. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
20. Tenari N, Lattanzio R, Natoli C, et al. Changes in topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res. 2006;12(5):1501-1506.
21. Ejlertsen B, Maj-Britt J, Nielsen KV, et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol. 2010;28:984-990.